Evidence mapPaperPMID 42367479Full record

ArticleCureus2026

Enhanced Apparent Oral Bioavailability of Berberine Through BioSOLVE Technology: Pharmacokinetic Evaluation of Metaberine™.

Shankaranarayanan Jeyakodi, Arunkanth Krishnakumar, Kiran DA

Abstract read
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shankaranarayanan JeyakodiResearch and Development, Zeus Hygia Life Sciences, Hyderabad, IND.
Arunkanth KrishnakumarResearch and Development, Zeus Hygia Life Sciences, Hyderabad, IND.
Kiran DAResearch and Development, Apollo Biosciences, Bengaluru, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Berberine is an isoquinoline alkaloid known for its potential role in supporting metabolic, cardiovascular, and gastrointestinal functions. Its clinical application, however, remains constrained by limited oral absorption, which is influenced by factors such as low solubility, restricted intestinal permeability, metabolism, and transport-mediated efflux. Purpose This study compared the oral pharmacokinetics of Metaberine™, a novel berberine formulation developed with BioSOLVE technology, against conventional berberine in male rats. The objective was to determine whether the formulation enhances peak plasma concentration (C

Indexed as

berberinebioavailabilitybiosolve technologymetaberinepharmacokinetics

Identifiers

PMID42367479
PMCPMC13310164

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.